Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial Meeting Abstract
| Authors: | Soria, J. C.; Goldman, J. W.; Wakelee, H.; Gadgeel, S.; Camidge, D. R.; Solomon, B.; Yu, H.; Oxnard, G. R.; Ou, S. H.; Papadimitrakopoulou, V.; Perol, M.; Reckamp, K.; Varga, A.; Dziadziuszko, R.; Chouaid, C.; Cortot, A.; Do, P.; Moro-Sibilot, D.; Poudenx, M.; Sequist, L. V. |
| Abstract Title: | Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial |
| Meeting Title: | 18th European Cancer Conference (ECCO 18) |
| Journal Title: | European Journal of Cancer |
| Volume: | 51 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2015 Sep 25-29 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2015-09-01 |
| Start Page: | S637 |
| Language: | English |
| ACCESSION: | WOS:000361887403063 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(16)31746-4 |
| Notes: | Meeting Abstract: 3105 -- Source: Wos |
